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Chronic myeloid leukemia (CML) is a myelo-
proliferative neoplasm that arises from break 
point cluster region/Abelson murine leuke-
mia viral oncogene homolog 1 (BCR/ABL)–
transformed hematopoietic stem (HSCs) or early 
progenitor cells known as leukemia stem cells 
(LSCs; Kavalerchik et al., 2008). LSCs have 
been first characterized as the tumor-initiating 
cells in acute myeloid leukemia (Lapidot et al., 
1994) and have also been defined in other he-
matopoietic neoplasms since then (Cox et al., 
2004; Matsui et al., 2004).
BCR/ABL-specific tyrosine kinase inhibi-
tors (TKIs) such as Imatinib mesylate (Glivec) 
have revolutionized the therapy of CML (Druker 
et al., 2001a,b; Baccarani et al., 2006). Never-
theless, LSCs seem resistant to TKIs and tra-
ditional chemotherapy (Weiden et al., 1979; 
Deininger et al., 2000; Savona and Talpaz, 2008) 
and CML inevitably progresses to incurable 
acute leukemia (Faderl et al., 1999). Quies-
cent, self-renewing LSCs remain in the BM 
and are responsible for refractoriness and re-
lapse of CML after treatment (Hughes et al., 
2003). Therefore, novel cytotoxic agents that 
selectively target LSCs are under investigation 
(Jin et al., 2006; Guzman et al., 2007; Neviani 
et al., 2007; Ito et al., 2008; Bellodi et al., 2009; 
Majeti et al., 2009; Wang et al., 2010; Schürch 
et al., 2012).
Another promising approach in the treatment 
of CML is immunotherapy. In fact, currently, 
the only curative treatment for CML remains 
allogeneic stem cell transplantation (alloSCT). 
The graft-versus-leukemia effect of alloSCT is 
most likely executed by donor CD8+ effec-
tor CTLs specific for minor histocompatibility 
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Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia arising from the 
oncogenic break point cluster region/Abelson murine leukemia viral oncogene homolog 1 
translocation in hematopoietic stem cells (HSCs), resulting in a leukemia stem cell (LSC). 
Curing CML depends on the eradication of LSCs. Unfortunately, LSCs are resistant to cur-
rent treatment strategies. The host’s immune system is thought to contribute to disease 
control, and several immunotherapy strategies are under investigation. However, the inter-
action of the immune system with LSCs is poorly defined. In the present study, we use a 
murine CML model to show that LSCs express major histocompatibility complex (MHC) and 
co-stimulatory molecules and are recognized and killed by leukemia-specific CD8+ effector 
CTLs in vitro. In contrast, therapeutic infusions of effector CTLs into CML mice in vivo 
failed to eradicate LSCs but, paradoxically, increased LSC numbers. LSC proliferation and 
differentiation was induced by CTL-secreted IFN-. Effector CTLs were only able to elimi-
nate LSCs in a situation with minimal leukemia load where CTL-secreted IFN- levels were 
low. In addition, IFN- increased proliferation and colony formation of CD34+ stem/
progenitor cells from CML patients in vitro. Our study reveals a novel mechanism by which 
the immune system contributes to leukemia progression and may be important to improve  
T cell–based immunotherapy against leukemia.
© 2013 Schürch et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 M
ay 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published February 11, 2013
606 CTLs induce proliferation of CML LSCs | Schürch et al.
sublethally irradiated (6.5 Gy) C57BL/6 (BL/6) recipient 
mice (Mumprecht et al., 2009a). As shown before (Mumprecht 
et al., 2009b), at this reduced irradiation dose the adaptive 
immune system, including CD8+ T cells, CD4+ T cells, and 
B cells, originates from the recipient mouse (Mumprecht et al., 
2009b), allowing us to generate CML in a BL/6 host with a 
largely intact immune system. To analyze the interaction of 
CTLs with defined antigen specificity with LSCs, we used 
donor BM of H8 transgenic mice (Ehl et al., 1998) that ubiq-
uitously express the LCMV glycoprotein epitope gp33 under 
the control of an MHC class I promoter to generate a CML 
in BL/6 mice (H8 CML). In this setting, BCR/ABL-GFP–
expressing cells coexpress the LCMV-gp33 antigen.
20 d after transplantation, H8 CML mice were sacrificed 
and BM was isolated. H8 LSCs were defined as BCR/ABL-
GFP+, lineage negative (lin), Sca-1+, c-kithi (Neering et al., 
2007) and analyzed for expression of MHC class I and II and 
co-stimulatory molecules by FACS (Fig. 1 A). MHC-I, 
MHC-II, CD80, and CD86 were all strongly expressed on 
H8 LSCs. In addition, LSCs expressed PD-L1 but not PD-L2. 
We next sought to determine the capacity of H8 LSCs to 
activate naive or reactivate memory LCMV-gp33–specific, 
TCR transgenic CD8+ T cells (p14 CTLs; Pircher et al., 
1989) in a standard 3H-thymidine incorporation assay. In the 
absence of additional cytokines, H8 LSCs induced prolifera-
tion not only in memory, but also in naive p14 CTLs (Fig. 1 
B and C). These data indicate that LSCs possess the molecu-
lar repertoire to interact with T cells and are able to induce 
proliferation of naive and memory CTLs.
To test whether effector CTLs are able to kill LSCs 
in vitro, we isolated LSCs from H8 CML and BL/6 CML 
mice by FACS. LSCs were co-incubated with either naive 
cells (ctrl) or p14 effector cells (p14) overnight, followed by 
colony-forming assays. Co-incubation of H8 LSCs with p14 
effector splenocytes resulted in significantly fewer colonies as 
compared with control naive splenocytes (Fig. 1 D). A titra-
tion of the effector/target ratio revealed an efficient lysis of 
H8 LSCs by MACS-purified p14 effector CD8+ CTLs in vitro. 
In contrast, p14 effector CD8+ CTLs did not lyse BL/6 LSCs 
(Fig. 1 E). These experiments revealed that LSCs are recog-
nized and killed by activated CTLs in vitro and that this 
killing is antigen specific.
Immunoediting of LSCs by endogenous CD8+ T cells in vivo
We next wanted to address the question of whether specific 
CTLs actually interact with LSCs in vivo. To this end, as an 
indirect parameter, we analyzed the immunogenicity of LSCs 
in the presence or absence of CD8+ T cells. We generated H8 
CML mice and treated them i.p. with depleting anti-CD8 
monoclonal antibody (mAb), starting 12 d after transplan-
tation. This treatment depletes CD8+ T cells from periph-
eral blood to below detection limits of FACS (not depicted) 
and leads to rapid CML progression (Mumprecht et al., 
2010). Control H8 CML mice were left untreated. 8 d 
later, we isolated LSCs from both groups of mice and per-
formed a 3H-thymidine assay using naive p14 CD8+ T cells 
antigens (Weiden et al., 1979; Kolb et al., 1990; Gale et al., 
1994; Druker et al., 2002). Patients who receive T cell–de-
pleted alloSCT grafts have a higher risk of disease relapse, and 
donor lymphocyte infusions are able to induce complete remis-
sion after relapse (Thomas et al., 1979; Horowitz et al., 1990; 
Kolb et al., 1995; Sehn et al., 1999). Furthermore, endogenous 
CTLs directed against leukemia antigens have been detected in 
the peripheral blood of chronic phase CML patients (Molldrem 
et al., 2000; Butt et al., 2005). Several proteins may potentially 
act as potent leukemia-specific antigens for T cells, including 
BCR/ABL, Wilms’ tumor 1 protein (WT1), and proteinase 3 
(Pr3; Van Driessche et al., 2005). Peptides from the junctional 
region of BCR/ABL are not present in healthy individuals and 
therefore are leukemia-specific. Yotnda et al. (1998) identified 
a BCR/ABL junctional nonapeptide that binds to human leu-
kocyte antigen (HLA)-A2.1 and elicits specific CTL responses 
in vitro and in vivo. Additional studies confirmed and extended 
the finding of immunogenic BCR/ABL junction peptides 
(Bocchia et al., 1996; Clark et al., 2001).
CTLs have been shown to kill CML target cells in vitro 
via Fas-receptor triggering (Selleri and Maciejewski, 2000). 
In a BCR/ABL-induced murine CML model, we have shown 
that CD8+ T cells crucially contribute to disease control in 
vivo. However, programmed death ligand 1 (PD-L1) expres-
sion by the malignant cells induced T cell dysfunction leading 
to disease progression (Mumprecht et al., 2009b).
Despite these advances in the understanding of the im-
munosurveillance of CML and the development of immuno-
therapy strategies, the interaction of effector CTLs with the 
disease-originating LSCs has not been analyzed so far. In 
the present study, we analyzed the immunogenicity of LSCs 
in vitro and in vivo using the glycoprotein of lymphocytic cho-
riomeningitis virus (LCMV) as model leukemia antigen. LSCs 
expressed MHC and co-stimulatory molecules. LSCs isolated 
from CD8+ T cell–depleted CML mice were more immuno-
genic than LSCs from control CML mice, indicating that CD8+ 
T cells interact with LSCs in vivo and select for low immuno-
genic variants. To analyze whether LSCs can be recognized and 
lysed by activated leukemia-specific effector CTLs, we treated 
CML mice with large numbers of specific T cells. Although 
these effector CTLs efficiently lysed LSCs in vitro, adoptive 
immunotherapy in vivo failed to eradicate LSCs but paradoxi-
cally increased LSC numbers. LSC proliferation was induced 
by CTL-secreted IFN-. Specific effector CTLs secreted high 
amounts of IFN- when transferred to CML mice in advanced 
disease stage with high antigen load, but not after transfer to 
CML mice in early stage of disease. Importantly, our results 
were confirmed in a humanized CML model using HLA-A2.1 
transgenic mice and a BCR/ABL b3a2 junctional peptide. In 
addition, IFN- induced the proliferation of primary CD34+ 
stem/progenitor cells from newly diagnosed CML patients.
RESULTS
Immunogenicity of LSCs in vitro
To establish a CML-like disease, BM cells were retrovirally 
transduced with BCR/ABL-GFP, followed by transfer to 
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CTL killing of LSCs in vivo is dependent  
on antigen/leukemia load
Our experiments thus far suggest that specific effector CTLs 
should be very efficient in the elimination of LSCs in vivo 
and therefore can be developed as a therapeutic strategy. To 
test the role of specific effector CTLs in a therapeutic setting 
with minimal leukemia load, we injected FACS-purified 
H8 LSCs into irradiated (6.5 Gy) secondary BL/6 recipient 
mice and adoptively transferred p14 effector CTLs 18 h later 
(Fig. 3 A). 2 d later, the numbers of BCR/ABL-GFP+ cells 
and LSCs in the BM were analyzed. In concordance with our 
in vitro experiments, the adoptive transfer of leukemia-specific 
CTLs drastically reduced the number of BCR/ABL-GFP+ 
cells and LSCs in the BM of p14 effector CTL-treated mice 
(Fig. 3, B and C). In line with these findings, primary H8 
CML mice treated 7 d after CML induction survived, whereas 
untreated controls died after 3 wk (Fig. 3 D). These experi-
ments indicate that LSCs can be recognized and killed by 
adoptively transferred specific CTLs in vivo.
as responders (Fig. 2 A). Interestingly, LSCs isolated from 
CD8-depleted H8 CML mice (CD8 LSCs) induced a more 
efficient expansion of naive p14 responder CD8+ T cells than 
LSCs from control H8 CML mice (LSCs).
To determine the immunogenicity of LSCs from CD8-
depleted hosts in vivo, we secondarily transplanted 2 × 104 
LSCs or CD8 LSCs to irradiated (6.5 Gy) BL/6 recipients. 
12 d after transplantation, secondary recipients had similar 
numbers of BCR/ABL-GFP+ granulocytes in peripheral 
blood, indicating similar engraftment of LSCs from both groups 
(Fig. 2 B). However, secondary CML originating from 
CD8 LSCs progressed much slower than secondary CML 
originating from control LSCs. This was reflected in a slower 
increase of BCR/ABL-GFP+ granulocytes in blood (Fig. 2 B) 
and a significantly prolonged survival of secondary recipients 
(Fig. 2 C). These experiments indicate that CD8+ T cells 
interact with LSCs in vivo. This interaction leads to a selective 
pressure to develop poorly immunogenic LSCs, a process 
called immunoediting (Schreiber et al., 2011).
Figure 1. Immunogenicity of CML LSCs in vitro. (A) Expression of MHC class I, MHC class II, CD80, CD86, PD-L1, and PD-L2 on H8 CML LSCs. 1 rep-
resentative plot of 3–10 is shown. (B and C) 3H-thymidine assays. (B) 3 × 103 FACS-purified, irradiated (10 Gy) LSC stimulators were co-incubated with  
1.5 × 104 MACS-purified CD8+ T cell responders from BL/6 mice infected with LCMV 6 wk earlier. One representative experiment out of two is shown.  
(C) 3 × 103 FACS-purified, irradiated (10 Gy) LSC stimulators were co-incubated with 1.5 × 104 MACS-purified CD8+ T cell responders from naive p14 TCR 
transgenic animals. One representative experiment out of five is shown. (D–E) In vitro killing assay. (D) 104 H8 LSCs FACS-purified from H8 CML mice at 
day 18 after transplantation were co-incubated with 2 × 104 naive BL/6 splenocytes (ctrl) or p14 effector splenocytes (p14) overnight, followed by trans-
fer into methylcellulose. Colonies were enumerated 7 d later. One representative experiment out of two is shown. (E) 104 FACS-purified H8 or BL/6 LSCs 
from H8 or BL/6 CML mice (20 d after CML induction) were co-incubated with 0, 103, 104, 105, 106, or 107 MACS-purified naive CD8+ T cells (ctrl) or p14 
effector CD8+ T cells (p14) overnight, followed by transfer into methylcellulose in duplicates. Colonies were enumerated 7 d later. Percent killing was cal-
culated in relation to culture condition without CD8+ T cells (0). Data are displayed as mean ± SEM. Statistics: Student’s t test (B–D), two-way ANOVA (E). 
*, P < 0.05; **, P < 0.005; ***, P < 0.0001. Isotype controls, blue lines; stainings, red lines. E:T, effector/target ratio; LSCs, leukemia stem cells; Resp.,  
responders; Stim., stimulators.
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transplantation, adoptively transferred p14 effector CTLs pro-
duced IFN-, resulting in detectable serum concentrations of 
IFN- (Fig. 4 A). The level of IFN- increased in dependence 
of the number of transferred p14 effector CTLs (Fig. 4 B). 
Intracellular stainings revealed that BM-infiltrating CTLs 
produced IFN- in CML mice (Fig. 4 C). Moreover, the 
IFN- receptor was expressed on H8 LSCs, suggesting that 
LSCs are able to respond to IFN- (Fig. 4 D).
To investigate the effect of IFN- on leukemia develop-
ment and the behavior of LSCs, we injected recombinant 
murine (rm)-IFN- or vehicle i.p. into BL/6 CML mice on 
2 consecutive days, starting 17 d after CML induction. IFN- 
treatment stabilized the number of Gr-1+ BCR/ABL-GFP+ 
granulocytes in the peripheral blood (before IFN-, 164 ± 
28/µl; after IFN-, 264 ± 38/µl; ns), whereas in vehicle-
treated mice, Gr-1+ BCR/ABL-GFP+ granulocyte numbers 
significantly increased during this time period (before vehicle: 
194 ± 69/µl; after vehicle: 879 ± 166/µl; P = 0.005, Fig. 4 E). 
In contrast, FACS analysis of BM after IFN- treatment 
(day 19) revealed a fivefold increase in LSC numbers com-
pared with vehicle-treated mice (Fig. 4 F), a finding that was 
confirmed by colony forming assays of lin cells (Fig. 4 G). 
Similar results with IFN- treatment were obtained in H8 
CML mice expressing the LCMV-gp33 as a model tumor 
antigen (not depicted).
To verify that the increase in LSCs detected in FACS 
analysis and in methylcellulose cultures in vitro actually rep-
resents an increase in cells that can induce leukemia in vivo, 
we secondarily transplanted 3 × 106 BM cells from vehicle- 
and IFN-–treated CML mice (day 19) into sublethally irra-
diated (4.5 Gy) BL/6 mice. Mice that received BM from 
IFN-–treated leukemia mice developed a more severe course 
of the disease and died significantly faster than control mice 
(Fig. 4, H and I).
To more closely model the clinical situation of leukemia, 
we treated H8 CML mice with p14 effector CTLs 20 d after 
primary leukemia transplantation. At this time point, the fre-
quency of Gr-1+ BCR/ABL-GFP+ granulocytes in the pe-
ripheral blood was 43 ± 9% (not depicted), indicating a high 
leukemia load. Injections of p14 effector CTLs significantly 
reduced total BM cells compared with untreated mice (Fig. 3 F). 
Surprisingly, when analyzing the lineage-negative fraction 
and LSCs in these mice, we found a drastic increase in total 
LSC numbers (Figs. 3 E, 3G) in p14 effector CTL-treated H8 
CML mice. This increase in LSCs was accompanied by a 
similar increase in host BCR/ABL-GFP, lin, Sca-1+, c-kithi 
(LSK) cells (Fig. 3, H and I) suggesting that a soluble factor 
secreted by effector CTLs, rather than a direct cell–cell inter-
action, is responsible for the observed effect. However, treat-
ment with p14 T cells at this late stage of disease did not 
improve survival (Fig. 3 J).
IFN- enhances proliferation of LSCs and leukemia 
progenitor cells in vivo
IFN- is a major effector cytokine secreted by effector CTLs 
(Farrar and Schreiber, 1993). In addition, recent studies have 
shown that interferons have the capacity to activate HSCs 
(Essers et al., 2009; Baldridge et al., 2010). Therefore, we an-
alyzed the concentration of IFN- in the sera of p14 effector 
CTL-treated CML mice. H8 LSCs were transplanted into 
secondary BL/6 recipient mice and p14 effector CTLs were 
adoptively transferred either 18 h or 16 d after LSC transplan-
tation. 2 d after adoptive transfer of p14 effector CTLs, serum 
IFN- levels were analyzed. IFN- concentrations were 
below the detection limit in sera of untreated CML mice and 
of CML mice that were treated with p14 effector CTLs 18 h 
after H8 LSC transplantation (Fig. 4 A). In contrast, in CML 
animals with an established leukemia 16 d after secondary 
Figure 2. Immunoediting of LSCs by endogenous CD8+ T cells in vivo. (A) 3H-thymidine assay. 3 × 103 FACS-purified, irradiated (10 Gy) LSC stimu-
lators from H8 CML mice (LSCs) or from CD8-depleted H8 CML mice (CD8 LSCs) were co-incubated with 1.5 × 104 MACS-purified CD8+ T cell responders 
from naive p14 TCR transgenic animals. Pooled data from two independent experiments are shown. (B and C) 2 × 104 FACS-purified LSCs (solid 
line, n = 9) or CD8 LSCs (dotted line, n = 10) were secondarily transplanted into irradiated (6.5 Gy) BL/6 recipient mice. (B) Numbers of BCR/ABL-GFP+ 
granulocytes/µl blood and (C) Kaplan-Meier-survival curves resulting from secondary transplantations. One representative out of three independent  
experiments is shown. Data are displayed as mean ± SEM. Statistics: Student’s t test (A), two-way ANOVA (B), and log-rank test (C). **, P < 0.005;  
***, P < 0.0001. Resp., responders; Stim., stimulators.
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leukemia common myeloid progenitors (CMPs) and leuke-
mia granulocyte-macrophage progenitors (GMPs). Upon 
IFN- treatment, leukemia CMP numbers increased as a re-
sult of proliferation (Fig. 5, K and L). Interestingly, although 
IFN- increased proliferation of leukemia GMPs, their abso-
lute numbers in BM were not increased (Fig. 5, M and N). 
This suggests that leukemia GMPs rapidly differentiate into 
more mature myeloid cells.
In summary, these experiments indicate that IFN- in-
creases the numbers of LSCs and leukemia progenitor cells by 
enhancing their proliferation.
LSCs are a heterogeneous population consisting of long-
term and short-term LSCs and leukemia multipotent pro-
genitor cells (MPPs; Li et al., 2012). We therefore determined 
the LSC subpopulation preferentially responding to rm-
IFN- (Fig. 5 A). IFN- increased numbers of primitive 
long-term and short-term LSCs, as well as early myeloid leu-
kemia MPPs (LMPPs) in BM (Fig. 5, B–E). In contrast, there 
was no difference in lymphoid-primed LMPPs (Fig. 5 F). 
IFN- increased leukemia c-kithi cells by enhancing their 
proliferation (Fig. 5, G and H); cell survival was not affected 
(Fig. 5, I–J). In addition, we analyzed more differentiated 
Figure 3. CTL-killing of LSCs in vivo 
depends on leukemia load. (A) Experimental 
design. 2 × 104 H8 LSCs from H8 CML mice 
were FACS-purified 20 d after transplantation 
and were transferred i.v. into irradiated (6.5 
Gy) secondary BL/6 recipients. 18 h later, mice 
were either left untreated (Ø, n = 4) or treated 
with 3 × 106 FACS-purified p14 CTLs i.v. (n = 4). 
48 h later, BM was harvested and analyzed  
for BCR/ABL-GFP+ cells (B) and LSCs (C) by 
FACS. Pooled data from two independent 
experiments are shown. (D) Kaplan-Meier 
survival curves resulting from H8 CML mice 
either left untreated (Ø, n = 5) or treated with 
5 × 106 p14 effector CTLs (p14, n = 5) 7 d 
after transplantation. (E–I) H8 CML mice 18 d 
after transplantation were either left un-
treated (Ø, n = 4) or treated with 3 × 106 
FACS-purified p14 effector CTLs (p14, n = 5). 
2 d later, (E) the frequencies of LSCs in 
linBCR/ABL-GFP+ cells, the numbers of total 
BM cells (F), the numbers of LSCs in the BM 
(G), the frequencies of LSK cells in linGFP 
cells (H), and the numbers of LSK cells in the 
BM (I) were analyzed. One representative plot 
of 4–5 is shown for each group. (J) Kaplan-
Meier survival curves resulting from H8 CML 
mice either left untreated (Ø, n = 9) or treated 
with 5 × 106 p14 effector CTLs (p14, n = 10) 
19 d after transplantation. Data are displayed 
as mean ± SEM. Statistics: Student’s t test  
(B, C, F, G, and I), log-rank test (D and J).  
*, P < 0.05; **, P < 0.005. LSCs, leukemia stem 
cells; LSK, linSca-1+c-kithi.  on
 M
ay 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published February 11, 2013
610 CTLs induce proliferation of CML LSCs | Schürch et al.
the same experimental setting prevented the rejection of leu-
kemia cells by p14 effector CTLs and increased LSC num-
bers. In addition, 3 × 106 BM cells from untreated, p14-treated, 
or p14+rm-IFN-–treated H8 CML mice were transplanted 
into sublethally (6.5 Gy) irradiated tertiary BL/6 recipient 
mice. Mice that received p14-treated BM did not develop 
leukemia, therefore they survived (Fig. 6, D and E). In con-
trast, mice receiving untreated BM or p14+rm-IFN-–treated 
BM developed leukemia and died from classical symptoms of 
leukemia (Fig. 6, D and E). These experiments indicate that 
IFN- increases LSC numbers and prevents the elimination 
of LSCs by CTLs. The increase of leukemia cells in the BM 
in response to IFN- is in contrast to the reduction of malig-
nant granulocytes after IFN- treatment in the circulation 
(Fig. 4 E), indicating that the effect on mature granulocytes 
and on leukemia stem/progenitor cells is different.
Next, we adoptively transferred p14 and p14xIFN-/ 
effector CTLs to primary H8 CML mice in an advanced 
Adoptively transferred CTLs increase the proliferation  
of leukemia progenitor cells via IFN-
To analyze if the observed increase of LSCs in CML mice 
after p14 effector CTL-treatment is indeed caused by IFN- 
secretion from CTLs, treatment protocols early and late after 
LSC transfer were repeated using IFN-–deficient p14 effec-
tor CTLs. First, secondary recipients were treated 18 h after 
LSC transplantation, either with IFN-–competent (p14) or 
–deficient (p14xIFN-/) p14 effector CTLs. 2 d later, 
numbers of BCR/ABL-GFP+ cells and LSCs were analyzed 
in the BM. P14 and p14xIFN-/ effector CTLs were equally 
able to eradicate BCR/ABL-GFP+ cells and LSCs at this 
early time point after LSC transfer (Fig. 6, A and B). In vitro 
cytotoxicity assays revealed that target cell lysis by p14 and 
p14xIFN-/ CTLs could be inhibited by addition of the 
granzyme B inhibitor Z-aminoactinomycin D (AAD)-CMK, 
but not by blocking the FAS–FASL interaction using mAb 
(Fig. 6 C). Importantly, additional injection of rm-IFN- in 
Figure 4. IFN- increases LSC numbers 
in CML. (A and B) IFN- serum levels of CML 
mice 48 h after p14 CTL treatment. (A) 2 × 104 
H8 LSCs were FACS-purified 20 d after pri-
mary transplantation and were transferred i.v. 
into irradiated (6.5 Gy) secondary BL/6 hosts. 
18 h or 16 d later, mice were either left un-
treated (Ø, n = 10, 18h) or treated with 3 × 
106 FACS-purified p14 CTLs i.v. (18h: n = 10; 
16d: n = 5). (B) H8 CML mice were treated 
with titrated numbers of MACS-purified p14 
CTLs (106, 5 × 106 or 10 × 106 cells) 16 d after 
primary transplantation or were left untreated 
(n = 6–7 mice per group). (C) IFN- produc-
tion of BM-infiltrating CTLs in BL/6 hosts that 
were treated 16 d after secondary LSC trans-
plantation (n = 5). (D) Expression of IFN- 
receptor  chain (IFN-R) on H8 CML LSCs. 
One representative plot of 5 is shown. (E-I) 
BL/6 CML mice were treated with either  
vehicle (VEH, n = 5) or 2.5 × 105 U of rm-IFN- 
(n = 6) i.p. twice daily on two consecutive 
days (days 17 and 18 after primary transplan-
tation). (E) Numbers of BCR/ABL-GFP+ granu-
locytes/µl blood and (F) LSC numbers were 
determined on day 19 after transplantation. 
(G) Equal numbers of lin cells were plated in 
methylcellulose and BCR/ABL-GFP+ colonies 
were enumerated 7 d later by fluorescence 
microscopy. (H-I) 3 × 106 BM cells from  
vehicle-treated (black line, n = 5) or IFN-–
treated (red line, n = 6) BL/6 CML mice were 
secondarily transplanted into irradiated (4.5 
Gy) BL/6 mice. (H) Numbers of BCR/ABL+ 
granulocytes/µl blood and (I) Kaplan-Meier 
survival curves resulting from secondary 
transplantations. Data are displayed as mean ± 
SEM. Statistics: Student’s t test (F and G), 
two-way ANOVA (E and H), log-rank test (I). 
*, P < 0.05; **, P < 0.01; ***, P < 0.0005.
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was confirmed by performing colony forming assays from 
lin BM and assessing the numbers of BCR/ABL-GFP+ col-
onies by fluorescence microscopy (Fig. 6 H). CML mice 
treated at this late stage of disease died rapidly a few days after 
treatment (Fig. 3 J), thus the effect on CML disease cannot 
be analyzed directly. To further confirm the increase in ma-
lignant progenitors in the BM of p14-treated mice, we sec-
ondarily transplanted 3 × 106 BM cells from untreated, 
p14-treated, or p14xIFN-/–treated H8 CML mice into 
sublethally irradiated (6.5 Gy) BL/6 mice. Monitoring sec-
ondary CML by repetitive bleeding revealed that mice re-
ceiving p14-treated BM developed CML and succumbed to 
lethal disease by day 18 after transplantation (Fig. 6, I and J). 
stage of the disease 17 d after transplantation. Control H8 
CML mice were left untreated. Before adoptive transfer, num-
bers of Gr-1+ BCR/ABL-GFP+ granulocytes in the peripheral 
blood were comparable (untreated, 728 ± 59/µl; p14-treated, 
719 ± 143/µl; p14x IFN-/–treated, 977 ± 139/µl; ns). 
Blood and BM were analyzed 2 d after adoptive transfer. In 
untreated mice, peripheral blood BCR/ABL-GFP+ granulo-
cyte numbers rapidly increased (Fig. 6 F). In contrast, p14 
effector CTLs and, to a lesser extent, p14xIFN-/ effec-
tor CTLs reduced the increase of BCR/ABL-GFP+ granu-
locytes after these 2 d (Fig. 6 F). Strikingly, we found a 
marked increase in total LSC numbers in p14-treated, but 
not p14xIFN-/–treated CML mice (Fig. 6 G). This finding 
Figure 5. IFN- enhances the proliferation of early LSCs and leukemia progenitor cells in vivo. (A) Gating strategy to identify early LSCs and 
leukemia progenitor cells in the BM of CML mice. (B–N) BL/6 CML mice were treated with either vehicle (VEH, n = 7) or 2.5 × 105 U of rm-IFN- (n = 5) 
i.p. twice daily on two consecutive days (days 17 and 18 after primary transplantation). On the same days, mice also received BrdU (0.8 mg/ml in 
drinking water and 1 mg i.p./day). 1 d later, linBCR/ABL-GFP+ BM cells were analyzed for LSCs and leukemia progenitor cells. (B) Long-term LSCs 
(c-kithiCD135CD48CD150+). (C) Short-term LSCs (c-kithiCD135CD48-CD150). (D) Leukemia MPP1s (c-kithiCD135CD48+CD150+). (E) Leukemia 
MPP2s (c-kithiCD135CD48+CD150). (F) Leukemia LMPPs (c-kithiCD135+CD150). (G) Numbers, (H) proliferation, and (I-J) viability of c-kithi leukemia pro-
genitor cells. Numbers (K) and proliferation (L) of leukemia CMPs (c-kithiCD127CD34+FcR). Numbers (M) and proliferation (N) of leukemia  
GMPs (c-kithiCD127CD34+FcR+). Data are displayed as mean ± SEM. Statistics: (B–N) Student’s t test. *, P < 0.05; ***, P < 0.0005. Apoptotic cells,  
Annexin V+ cells; necrotic cells, AnnexinV+7-AAD+ cells. CMPs, common myeloid progenitors; GMPs, granulocyte-macrophage progenitors; LMPPs, lymphoid-
primed multipotent progenitors; LT, long-term; MPPs, multipotent progenitors; ST, short-term.
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Figure 6. CTL-secreted IFN- increases LSC numbers. (A) 2 × 104 H8 LSCs were FACS-purified 20 d after transplantation and were transferred i.v. 
into irradiated (6.5 Gy) secondary BL/6 recipients. 18 h later, mice were either left untreated (Ø, n = 11) or treated with 3 × 106 FACS-purified p14 (n = 12) 
or p14xIFN/ (n = 3) CTLs i.v. One group of mice received p14 CTLs and was treated with 2.5 × 105 U of rm-IFN- twice daily for two consecutive days 
(n = 5). After 48 h, BM was harvested and analyzed for BCR/ABL-GFP+ (A) cells and LSCs (B) by FACS. Pooled data from two independent experiments are 
shown. (C) Duplicates of bulk BM cells from H8 CML mice were either incubated alone or were co-cultured with CTLs at a ratio of 5:1 with or without  
10 µg/ml anti–FAS-ligand, in the presence or absence of the indicated concentrations of the granzyme B inhibitor Z-AAD-CMK. After 4 h, the killing of 
BCR/ABL-GFP+ cells was determined. (D and E) 3 × 106 BM cells from p14-treated (red line, n = 5), p14+rm-IFN-–treated (blue line, n = 5), or untreated 
(black line, n = 10) H8 CML mice were tertiarily transplanted into irradiated (6.5 Gy) BL/6 mice. Numbers of BCR/ABL-GFP+ granulocytes/µl blood (D) and 
Kaplan-Meier survival curves (E) resulting from tertiary transplantations are shown. (F) BCR/ABL-GFP+ granulocytes in blood of primary H8 CML mice either left 
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leukemia progenitor cells, we purified lin BCR/ABL-
GFP+ c-kithi cells by FACS and performed an analysis of the 
cell cycle using DAPI staining. BCR/ABL-GFP+ c-kithi 
cells from p14-treated H8 CML mice were highly signifi-
cantly more in S-phase than BCR/ABL-GFP+ c-kithi cells 
from untreated or p14xIFN-/–treated mice (Fig. 6 M), 
indicating that CTL-secreted IFN- increases the prolifera-
tion of leukemia progenitor cells. A similar increase of cells 
in S-phase was observed for nonmalignant c-kithi in these 
mice (not depicted).
The experiments so far suggested that the increased IFN- 
production after CTL transfer to a CML mouse with high 
leukemia load but not with low leukemia load is caused by 
differences in antigen load. To confirm this experimentally, 
we transferred H8 LSCs into sublethally irradiated (6.5 Gy) 
H8 recipient mice and analyzed the effects of specific CTL 
therapy 18 h after adoptive transfer (Fig. 7 A).
In this experimental setup, the leukemia load is low, 
but all host cells express gp33 on MHC-I. Transfer of p14 
and p14xIFN/ effector CTLs had no or only a marginal 
effect on the numbers of BCR/ABL-GFP+ cells in the BM 
(Fig. 7 B). In contrast, LSC numbers increased in p14-treated 
In contrast, mice receiving untreated BM or p14xIFN-/–
treated BM developed CML substantially slower and survived 
significantly longer (Fig. 6, I and J).
We next sought to analyze how IFN- protects LSCs 
from CTL-mediated lysis, or even increases their numbers. 
Therefore, we analyzed the lysis of H8 LSCs from vehicle- or 
IFN-–treated H8 CML mice in vitro. We isolated BCR/
ABL-GFP+ c-kithi cells by FACS and co-incubated them di-
rectly ex vivo either with naive BL/6 or p14 effector CD8+  
T cells overnight, followed by colony-forming assays (Fig. 6 K). 
These experiments revealed that BCR/ABL-GFP+ c-kithi 
cells from vehicle- and IFN-–treated CML mice were simi-
larly killed by effector CTLs. In addition, the mean fluores-
cence intensities of MHC-I, MHC-II, CD80, and PD-L1 and 
PD-L2 were significantly up-regulated on BCR/ABL-GFP+ 
c-kithi cells from IFN-–treated CML mice (Fig. 6 L).
A similar lysis of IFN-–treated and control LSCs ex-
cludes the possibility that IFN- prevents CTL-mediated 
lysis of LSCs. Therefore, the observed IFN-–dependent 
increase in LSC numbers might be caused by an increase 
in LSC proliferation. To investigate whether adoptively 
transferred p14 effector CTLs induce proliferation of myeloid 
untreated (Ø) or treated with 3 × 106 FACS-purified p14 CTLs or p14xIFN-/ CTLs (n = 8 each). LSC numbers (G) and BCR/ABL-GFP+ colonies per mouse 
(H) 2 d after adoptive transfer. (I–J) 3 × 106 BM cells from primary H8 CML mice left untreated (black line, n = 8) or treated with p14 CTLs (red line, n = 8) 
or p14xIFN-/ CTLs (green line, n = 11) were secondarily transplanted into irradiated (6.5 Gy) BL/6 mice. (I) Numbers of BCR/ABL+ granulocytes/µl blood 
and (J) Kaplan-Meier survival curves resulting from secondary transplantations. (K) H8 CML mice were treated with either vehicle (VEH, n = 5) or 2.5 × 105 U 
of rm-IFN- (n = 5) i.p. twice daily on two consecutive days (d17 and d18 after primary transplantation). 2.5 × 104 FACS-purified H8 BCR/ABL-GFP+ c-kithi 
cells from VEH- or IFN-–treated H8 CML mice were co-incubated with 2.5 × 104 naive BL/6 CD8+ T cells (ctrl) or p14 CTLs (p14) overnight, followed by 
transfer into methylcellulose in duplicates. Colonies were enumerated 7 d later. (L) Mean fluorescent intensity (MFI) of MHC class I, MHC class II, CD80, 
CD86, PD-L1 and PD-L2 on LSCs from VEH- or IFN-–treated H8 CML mice. (M) Cell cycle analysis by DAPI stainings of total c-kithi cells from primary  
H8 CML mice left untreated (Ø, n = 6) or treated with p14 (n = 5) or p14xIFN-/ (n = 5) CTLs. Data are displayed as mean ± SEM. Statistics: one-way 
ANOVA (A, B, G–H, and M), two-way ANOVA (D and I), Student’s t test (K and L), and log-rank test (E and J). *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
 
Figure 7. CML treatment with CTLs specific for a ubiquitously expressed antigen increases LSC numbers. (A) Experimental design. 2 × 104 H8 
LSCs were FACS-purified 20 d after transplantation and were transferred i.v. into irradiated (6.5 Gy) secondary H8 hosts. 18 h later, mice were either left 
untreated (Ø, n = 15) or treated with 3 × 106 FACS-purified p14 (n = 16) or p14xIFN-/ (n = 11) CTLs i.v. After 48 h, BM was harvested and analyzed  
for BCR/ABL-GFP+ cells (B) and LSCs (C) by FACS. (D) In one experiment, serum IFN-y levels were determined 48 h after CTL transfer (n = 4–7 mice per 
group). (B and C) Pooled data from four independent experiments are shown. Data are displayed as mean ± SEM. Statistics: one-way ANOVA (B and C).  
***, P < 0.0001.
 o
n
 M
ay 12, 2014
jem.rupress.org
D
ow
nloaded from
 
Published February 11, 2013
614 CTLs induce proliferation of CML LSCs | Schürch et al.
a situation with high leukemia load or in a situation where 
the targeted antigen is not leukemia-specific but widely 
expressed in other tissues.
Adoptive immunotherapy using BCR/ABL junctional  
peptide-specific CTLs increases LSC numbers  
in a humanized CML model
The use of the LCMV-gp33 as a model tumor antigen has the 
advantage that TCR transgenic mice are available and that the 
mice (Fig. 7 C). This increase in LSC numbers is attributed 
to CTL-secreted IFN- as indicated by elevated IFN- serum 
levels (Fig. 7 D). Treatment with p14xIFN-/ effector 
CTLs neither increased LSC numbers nor IFN- serum 
levels (Fig. 7 C, D).
In summary, our experiments indicate that CTLs are 
able to eradicate LSCs in vitro and in vivo in a setting with 
minimal leukemia load. In contrast, LSC numbers increase 
because of CTL-secreted IFN- if T cell therapy is applied in 
Figure 8. CTL treatment paradoxically increases LSCs in a humanized CML model. HLA-A2tg CML mice 19 d after transplantation were either left 
untreated (Ø, n = 5) or treated with BCR/ABL b3a2 junction peptide-specific HLA-A2tg CD8+ T cells (+b3a2-CTLs, n = 4). In a similar, independent experiment, 
mice were left untreated (Ø, n = 8) or treated with HIV SL9 peptide-specific HLA-A2tg CD8+ T cells (+SL9-CTLs, n = 6). 1 d later, mice were bled and sacrificed 
for analysis. (A) Numbers of BCR/ABL-GFP+ granulocytes/µl blood before and 1 d after adoptive transfer of b3a2-CTLs. (B) BM was lineage depleted and ana-
lyzed by FACS for the expression of c-kit and Sca-1 after adoptive transfer of b3a2-CTLs. One representative plot of four untreated and five b3a2-CTL–treated 
HLA-A2tg CML mice is shown. (C and F) LSC numbers per mouse 1 d after adoptive transfer. (D and G) Equal numbers of lin cells were plated in methylcel-
lulose and BCR/ABL-GFP+ colonies were enumerated 7 d later by fluorescence microscopy. (E and H) 3 × 106 BM cells from HLA-A2tg CML mice left untreated 
(n = 4–8), treated with BCR/ABL b3a2-junction peptide-specific HLA-A2tg CTLs (n = 4), or treated with HIV SL9 peptide-specific HLA-A2tg CD8+ T cells (+SL9-
CTLs, n = 6) were secondarily transplanted into irradiated (6.5 Gy) HLA-A2tg mice. Kaplan-Meier survival curves resulting from secondary transplantations are 
shown. Data are displayed as mean ± SEM. Statistics: Student’s t test (C, D, F, and G) and log-rank test (E and H). *, P < 0.05; **, P < 0.01.
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In summary, these data indicate that IFN- increases the 
numbers of primary CD34+ stem/progenitor cells from blood 
and BM from newly diagnosed CML patients by enhancing 
their proliferation.
DISCUSSION
The long-term success of a leukemia treatment depends on 
its effect on LSCs. Unfortunately, LSCs are selectively resis-
tant against most current treatment strategies, including chemo-
therapy and TKIs (Weiden et al., 1979; Deininger et al., 2000; 
Savona and Talpaz, 2008). In contrast, the susceptibility of 
LSCs to immune therapies is less clear, and it is suspected 
that T cells and NK cells are able to eliminate residual tumor 
cells after cytoreduction in the BM (Kurz et al., 2010). How-
ever, although LSCs were identified more than a decade ago, 
the interaction of the adaptive immune system with LSCs 
is poorly defined. Therefore, we addressed the interaction 
of CTLs with LSCs in vitro and in vivo. Surprisingly, LSCs 
expressed high levels of MHC class I and II, as well as co-
stimulatory molecules. Therefore, they acted very efficiently 
as antigen-presenting cells and were able to induce the prolif-
eration of naive CTLs even in the absence of additional co-
stimulatory molecules or cytokines. Similarly, effector CTLs 
efficiently eliminated LSCs in vitro. These characteristics sug-
gest that a T cell–mediated therapy could efficiently target 
LSCs also in vivo. However, immunotherapy with identi-
cally activated CTLs did not eliminate, and in fact increased, 
the number of LSCs in vivo.
LSCs retain many characteristics of HSCs and reside in 
and probably depend on the HSC niche in the BM. For ex-
ample, blocking CD44 suppresses both AML and CML pro-
gression and induces differentiation, probably by disrupting 
the interaction between LSCs and the BM niche (Jin et al., 
2006; Krause et al., 2006). BM niche cells express membrane-
bound and secreted factors that regulate HSC quiescence, 
differentiation, and migration (Kiel and Morrison, 2008; 
Wilson et al., 2007). Therefore, the microenvironment in 
the HSC niche might be protective for LSCs in vivo and 
prevent CTL-mediated lysis. Two experiments argue against 
this possibility. First, CTLs were able to eliminate LSCs 18 h 
after transfer in vivo, a time period that is sufficient for 
HSCs and LSCs to migrate to the niche (Colvin et al., 2007; 
Bhattacharya et al., 2009; Xie et al., 2009; Capron et al., 2010). 
Second, CD8+ T cell depletion in CML mice increased the 
immunogenicity of LSCs, as documented by a more efficient 
stimulation of naive T cells in vitro and a more efficient rejec-
tion in secondary transplantation experiments. This strongly 
suggests that LSCs in vivo are accessible to effector CTLs 
and that effector CTLs select for low immunogenic variants. 
For solid tumors, it has been demonstrated that in equilib-
rium, the immune system is able to control occult tumor cells 
over a prolonged period of time while selecting for lower 
immunogenic variants that ultimately escape immune surveil-
lance and lead to tumor progression (Schreiber et al., 2011). 
Our data suggest that LSCs undergo a similar immunoediting 
expression of the antigen can be clearly controlled using trans-
genic animals. However, results may differ if a relevant leukemia 
antigen is targeted. Therefore, we made use of 2-microglob-
ulin (2m)/HLA-A2.1 monochain transgenic, H2-Db/2m 
double knock-out mice (HLA-A2tg mice; Pascolo et al., 1997). 
HLA-A2tg mice were repeatedly immunized with autologous 
DCs pulsed with a HLA-A2.1–binding junctional fusion on-
coprotein (SSKALQRPV, b3a2) derived from BCR/ABL 
(Yotnda et al., 1998) to induce b3a2-specific CTLs. Spleens 
were harvested after 14 d, and CD8+ T cells were purified, cul-
tured in vitro, and were stimulated (weekly) with autologous, 
b3a2 peptide-pulsed DCs to select for b3a2-specific T cell lines. 
After 3 wk of restimulation, MACS-purified b3a2-specific 
CTLs were injected into HLA-A2tg CML mice, and control 
mice were left untreated. Again, we observed a block in the 
increase of BCR/ABL-GFP+ granulocytes in the peripheral 
blood after adoptive T cell therapy (Fig. 8 A). FACS analysis 
of BM revealed that LSCs increased in frequency (Fig. 8 B) 
and in absolute numbers (Fig. 8 C) after b3a2-specific CTL 
treatment, which was confirmed by colony-forming assays of 
lin cells (Fig. 8 D). Most importantly, secondary transplan-
tations of 3 × 106 BM cells from CTL-treated HLA-A2tg 
CML mice into sublethally irradiated (6.5 Gy) HLA-A2tg 
mice led to rapid death of secondary recipients, whereas sec-
ondary recipients receiving BM from untreated HLA-A2tg 
CML mice survived substantially longer (Fig. 7 E).
To analyze if the effects on LSCs after CTL treatment 
require antigen specificity for the leukemia antigen, we 
performed a control experiment using CTLs specific for 
the HLA-A2.1–binding HIV peptide (SLYNTVATL, SL9; 
Brander et al., 1998). The number of LSCs in BM (Fig. 8 F) 
and BCR/ABL-GFP+ colony-forming capacity of lin cells 
(Fig. 8 G) was not affected by SL9-specific CTL treatment. 
In addition, we observed similar survival in mice second-
arily transplanted with BM from untreated or SL9 CTL-
treated primary HLA-A2tg CML (Fig. 8 H).
Therefore, BCR/ABL fusion protein–specific effector CTLs 
specifically increase the numbers of LSCs and confirm the results 
obtained with LCMV-gp33 as a model leukemia antigen.
IFN- increases proliferation and colony formation  
of primary CD34+ stem/progenitor cells from CML patients
To extend our findings to primary human CML stem/progen-
itor cells, we stained the IFN- receptor on CD34+ cells from 
newly diagnosed CML patients (initial leukocyte count, 169.9 ± 
93.2 × 109/liter). The IFN- receptor was expressed on CD34+ 
stem/progenitor cells in peripheral blood and BM, suggesting 
that CML stem cells are able to respond to IFN- (Fig. 9 A). 
Recombinant human (rh)-IFN- enhanced the proliferation 
of FACS-purified CD34+ stem/progenitor cells from CML 
patients in liquid cultures in vitro, resulting in increased BrdU 
incorporation and elevated cell numbers after 7 d of culture 
(Fig. 9, B and C). Cell death was not affected by rh-IFN- 
(Fig. 9, D and E). Furthermore, rh-IFN- increased the col-
ony-forming capacity of CD34+ stem/progenitor cells from 
CML patients (Fig. 9 F).
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with SCF and IL-3, IFN- stimulates differentiation of the 
granulocyte-monocyte and erythropoietic lineages in vitro 
(Kurz et al., 2010). More recently, IFN- was recognized 
as important mediator of infection-induced myelopoiesis 
(MacNamara et al., 2011). In a murine model of malaria 
infection, IFN- induced a unique myelolymphoid pro-
genitor population that gave rise to mostly myeloid cells 
(Belyaev et al., 2010). Other studies have shown that IFN- 
directly induces the expansion of lin Sca-1+ c-kit+ cells 
(Zhao et al., 2010) and that IFN-–induced genes are criti-
cal for HSC survival and maintenance (Baldridge et al., 
2010). We now documented a comparable effect of IFN- 
on LSCs. IFN- induced proliferation of leukemia progeni-
tor cells in our CML model as well as in primary CD34+ 
CML stem/progenitor cells from newly diagnosed patients. 
In the murine model, an increase in disease-initiating LSCs 
was documented in a secondary transplantation experiment 
where CML progression was faster after transplantation of 
IFN-–treated LSCs. In addition, IFN- treatment up-
regulated the inhibitory molecules PD-L1 and PD-L2 on 
LSCs, probably contributing to LSC immune escape in vivo 
(Zou and Chen, 2008). Thus, IFN- evolutionary evolved as 
process. In the experimental conditions chosen in our mu-
rine CML model, progression and death occur after 3–4 wk. 
In contrast, in human CML, the chronic phase lasts 3–5 yr be-
fore outgrowth of blasts that have acquired additional muta-
tions (Sawyers, 1999).
Type I IFNs (IFN- and -) and type II IFN (IFN-) 
are important cytokines in the control of infections (Kurz 
et al., 2010). As the elimination of an infectious pathogen 
requires a concerted action of different elements of the 
immune system it is not surprising that IFNs have direct 
effects on hematopoiesis. IFN- activates dormant HSCs 
to enter proliferation. In contrast, chronic activation of the 
IFN- pathway in HSC impairs their function, probably as 
a result of exhaustion (Essers et al., 2009). Before the intro-
duction of TKIs, IFN- was used as standard therapy for 
CML (Sawyers, 1999). In addition, T cell–derived cytokines 
have been described to influence hematopoiesis (Metcalf, 
2008). IFN- induces apoptosis of erythroid progenitors 
and BM cultures in vitro (Means, 1995; Wang et al., 1995) 
and may be a central cytokine in the induction of acquired 
aplasia (Young, 2006) and in anemia of chronic disease 
(Weiss and Goodnough, 2005). In contrast, in combination 
Figure 9. IFN- increases proliferation and colony formation of primary CD34+ stem/progenitor cells from CML patients. (A) Expression of 
IFN- receptor  chain (IFN-R) on CD34+ stem/progenitor cells from newly diagnosed CML patients. One representative plot of four is shown. 
(B–E) 104 FACS-sorted CD34+ cells from the peripheral blood or BM were cultured in the presence or absence of rh-IFN- for 7 d in sextuplicates. At day 
7 of culture, BrdU incorporation (B), cell numbers (C), apoptosis (D), and necrosis (E) were assessed in duplicates or triplicates. (F) 2 × 103 FACS-sorted 
CD34+ cells were cultured in methylcellulose in triplicates and colony-forming capacity was determined after 14 d. Data are displayed as mean ± SEM. 
Statistics: Student’s t test. **, P < 0.005; ***, P < 0.0001. Apoptotic cells, Annexin V+ cells; necrotic cells, Annexin V+7-AAD+ cells. P, Patient; VEH, vehicle.
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MATERIALS AND METHODS
Mice. C57BL/6J (BL/6) mice were obtained from RCC Ltd. CD45.1+ 
mice. p14 TCR transgenic mice (Pircher et al., 1989) specific for the LCMV 
glycoprotein epitope 33–41 (gp33), H8 transgenic mice (Ehl et al., 1998) ubiq-
uitously expressing LCMV-gp33 under the control of an MHC class I pro-
moter, IFN-–deficient mice (Dalton et al., 1993), and 2m/HLA-A2.1 
monochain transgenic, H2-Db/2m double knock-out mice (HLA-A2tg 
mice; Pascolo et al., 1997) were obtained from the Institute for Laboratory Ani-
mals (Zürich, Switzerland). Animal experiments were approved by the local 
experimental animal committee of the Canton of Bern and performed accord-
ing to Swiss laws for animal protection.
Patients. Peripheral blood samples and one BM aspirate from untreated, 
newly diagnosed CML patients (n = 3; age, 54.6 ± 19.4 yr) were ob-
tained at the University Hospital of Bern, Switzerland, in 2011 and 2012. 
All CML patients possessed a BCR/ABL translocation as tested by mo-
lecular analysis from the blood. Analysis of blood and BM samples was 
approved by the local ethical committee of the Canton of Bern and all 
patients gave written, informed consent.
Virus and peptides. LCMV strain WE was provided by R.M. Zinkernagel 
(University of Zürich, Zürich, Switzerland) and propagated on L929 
fibroblasts as previously described (Matter et al., 2006; Mumprecht et al., 
2006). The HLA-A2.1–binding BCR/ABL b3a2-junction peptide (aa 
926–934, SSKALQRPV; Yotnda et al., 1998) was purchased from Innovative 
Peptide Solutions. The MHC-II–specific LCMV glycoprotein peptide p13 
(aa 61–80, GLNGPDIYKGVYQFKSVEFD) was purchased from NeoMPS 
SA. The HIV peptide SL9 (aa 77–85, SLYNTVATL; Brander et al., 1998) 
was provided by D. Yerly (University of Bern, Bern, Switzerland).
Antibodies. H2-Db-PE, I-A/I-E-PE, c-kit-PE and -PE-Cy7, Sca-1-
perinidin-chlorophyll-protein (PerCP)-Cy5.5 and –allophycocyanin (APC), 
Ly6G-PE, Gr1-PE and –APC; CD80-PE, CD86-APC, IFN-–
PE, IFN--R-PE, IFN--R-PE, Armenian hamster-IgG-PE, PD-L1-
PE, CD127-PE, and -APC were obtained from eBioscience. CD11c-FITC, 
I-A/I-E-APC-Cy7, c-kit-APC-Alexa750, CD80-Pacific Blue, mouse-
IgG2b-PE, rat-IgG2a-APC, rat-IgG2b-APC-Cy7, Armenian hamster-IgG-
Pacific Blue, CD3-biotin, CD19-biotin, Gr1-biotin, Ter119-biotin, 
PD-L2-PE, -human-IFN--R-PE, LEAF-purified anti-FAS-ligand, 
LEAF-purified Armenian hamster-IgG isotype control, and Annexin 
V-Pacific Blue were purchased from BioLegend. Annexin V-FITC was ob-
tained from ImmunoTools. 7-Aminoactinomycin D (AAD), BrdU-APC 
(3D4), and the corresponding isotype control (MOPC21) were obtained 
from BD. CD8 (2.43) was purchased from BioXCell, and IgG from rat 
serum was purchased from Sigma-Aldrich.
Retroviral particles. The retroviral vector pMSCV-p210BCR/ABL-IRES-
GFP and the packaging vector pIK7 were a gift from J. Schwaller (University 
of Basel, Basel, Switzerland). Retroviral particles were produced and titrated 
as previously described (Mumprecht et al., 2009a).
CML model. CML was induced and monitored as previously described 
(Mumprecht et al., 2009a,b). In brief, 4 × 106 BM cells of 5-fluorouracil–
pretreated BL/6 mice, H8 mice, or HLA-A2tg mice were transduced 
twice in transplant medium with 105 retroviral particles through spin in-
fection. 105-transduced BM cells were injected i.v. into previously suble-
thally irradiated BL/6 recipient mice (BL/6 → BL/6, BL/6 CML; irradiation, 
4.5 Gy; H8 → BL/6, H8 CML; irradiation, 6.5 Gy) or HLA-A2tg mice 
(HLA-A2tg → HLA-A2tg, HLA-A2tg CML; irradiation: 6.5 Gy). 5 × 105 
transduced BM cells were incubated for 3 d in transplant medium, and 
GFP expression was analyzed by FACS. For secondary whole BM trans-
plantations, 3 × 106 BM cells from primary CML mice (18–20 d after pri-
mary transplantation) were injected i.v. into previously sublethally irradiated 
(6.5 Gy) secondary recipients.
an important regulator of infection- or stress-induced my-
elopoiesis. However, the same IFN-–mediated effects on 
LSCs induce their proliferation and disease progression.
Therefore, the adoptive transfer of specific CTLs affected 
leukemia development in different ways. It eliminated leuke-
mia granulocytes, and probably LSCs as well, and selected for 
low immunogenic LSC variants. Alternatively, CTL-secreted 
IFN- established a cytokine environment that facilitated 
leukemia progression. It is well documented that effector mech-
anisms of the immune system contribute to tumor control as 
well as to tumor progression (Schreiber et al., 2011). Whether 
effector CTLs, in addition to their tumor-protective role, 
may also enhance tumor growth, is less clear. In addition to 
IFN-, we recently showed that T cells contribute to leuke-
mia progression via the co-stimulatory CD70–CD27 inter-
action (Schürch et al., 2012).
The expansion of the LSC population clearly depended on 
IFN-, whereas the lytic effect on leukemia cells was indepen-
dent of IFN- and mediated by perforin/granzyme B. The level 
of IFN- produced after adoptive T cell transfer depended on 
the antigen-load in the leukemia mouse. We used the LCMV-
gp33 antigen as leukemia antigen to be able to control for the 
expression of the antigen. When gp33 was expressed also on 
nonleukemic host cells, or when the leukemia load was high and 
gp33-expressing cells were abundant, the transferred cells were 
restimulated in vivo to produce high amounts of IFN-. Simi-
larly, adoptive transfer of a BCR/ABL fusion protein–specific 
CTL line induced the expansion of LSCs in the humanized 
CML model, confirming that our findings are not specific for 
LCMV gp33. In addition, IFN- induced cell-cycling and ex-
pansion of primary human CD34+ CML stem/progenitor cells, 
indicating the relevance of this pathway for human disease.
In contrast, in a situation with a low leukemia load resem-
bling minimal residual disease, restimulation of the transferred 
CTLs did not lead to IFN- levels sufficient to induce LSC 
expansion. This fits well with clinical observations. Although 
recent studies showed that chimeric antigen receptor-modified 
T cells are able to eliminate up to 1kg of leukemia mass (Porter 
et al., 2011), it is generally accepted that immunotherapy is most 
efficacious in the presence of a low leukemia load (Carlens 
et al., 2001; Raiola et al., 2003). Therefore, most immuno-
therapies including alloSCT and donor lymphocyte infusions 
are applied after induction chemotherapy (Kolb et al., 1990; 
Kolb et al., 1995; Weiden et al., 1979). Independent of the 
leukemia load, the expression of the target antigen is crucial 
for the efficacy of adoptive T cell therapy. Our results reveal 
that even in a situation with a low leukemia load, the transfer 
of T cells that target an antigen that is widely expressed in the 
body leads to restimulation of the transferred T cells and se-
cretion of high amounts IFN-. This leads to proliferation of 
LSCs and precludes the success of the therapy.
Our study now documents that LSCs are immunogenic 
and can be targeted by specific CTLs, provided that the tar-
get antigen is leukemia specific and that the immunotherapy 
is applied in a situation with a low leukemia load, probably 
after cytoreduction.
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added, and the incorporation of radioactivity was detected on a TopCount 
microplate scintillation counter (PerkinElmer).
Colony-forming assays. 5 × 103 MACS-purified lineage-negative cells 
from CML mice were plated into MethoCult M3134 medium (STEMCELL 
Technologies) supplemented with 15% FCS, 20% BIT (50 mg/ml BSA in 
IMDM, 1.44 U/ml rh-insulin [Actrapid; Novo Nordisk], and 250 ng/ml 
human holo transferrin [Prospec]), 100 µM 2-mercaptoethanol, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2 mM l-glutamine, and 50 ng/ml rm-SCF, 
10 ng/ml rm-IL-3, 10 ng/ml rh-IL-6, and 50 ng/ml rm-Flt3-ligand (all from 
Prospec). BCR/ABL-GFP+ colonies were enumerated after 7 d (≥30 cells/
colony) on a DMIL inverted microscope (Leica) equipped with an Intensi-
light C-HGFI unit (Nikon).
2 × 103 FACS-purified CD34+ stem/progenitor cells from peripheral 
blood and BM of CML patients were plated into MethoCult H4435 En-
riched medium (STEMCELL Technologies) in the presence or absence of 
500 U/ml rh-IFN- (Prospec). Colonies and cells were enumerated after 
14 d (≥30 cells/colony).
In vitro LSC killing assay. 104 FACS-sorted H8 or BL/6 LSCs were 
co-cultured overnight in 96-well V-bottom plates (Corning) with titrated 
numbers of naive cells or p14 effector cells (either total splenocytes or 
MACS-purified CD8+ T cells). On the next day, the contents of wells 
were resuspended and colony assays were performed.
In vitro BCR/ABL-GFP+ leukemia cell killing assay. p14 or p14xIFN-
/ CTLs were generated as described in Generation of p14 and p14xIFN-
/ effector CTLs and memory cells and were isolated by MACS from 
spleens and lymph nodes. CTLs were preincubated for 20 min with or with-
out 10 µg/ml anti–FAS-ligand (MFL4; BioLegend), in the presence or ab-
sence of titrated concentrations of the granzyme B inhibitor Z-AAD-CMK 
(1, 10, and 100 mM; Enzo Life Sciences). Armenian hamster IgG (HTK888; 
BioLegend) and water served as negative controls, respectively. Bulk BM 
cells from H8 CML mice (containing 20% of BCR/ABL-GFP+ cells) 
were either incubated alone or were co-cultured with CTLs at a ratio of 5:1 
in the presence or absence of the indicated compounds in 24-well tissue cul-
ture plates. After 4 h, cells were analyzed by FACS and the killing of BCR/
ABL-GFP+ cells was calculated in relation to control conditions.
In vitro liquid culture of primary human CD34+ CML stem/progeni-
tor cells. 104 FACS-purified CD34+ stem/progenitor cells from the periph-
eral blood and BM of CML patients were cultured in StemSpan SFEM 
medium (Stem Cell Technologies) supplemented with human cytokines 
(StemSpan CC100; Stem Cell Technologies) in the presence or absence of 
500 U/ml rh-IFN- in 96-well plates at 37°C and 5% CO2 in sextuplicates. 
10 µM BrdU (BD) was added to culture for the last 4 h of incubation. Num-
bers of viable cells were determined by trypan blue staining and BrdU staining 
was performed according to the manufacturer’s instructions (BrdU Flow kit; 
BD) after 7 d of culture.
IFN- treatment of CML mice. CML mice were treated with 2.5 × 105 
U of rm-IFN- (Prospec) i.p. twice daily on two consecutive days, 16–18 d 
after primary transplantation or 18 h after secondary transplantation (a total 
of 106 U per animal).
CD8+ T cell depletion in vivo. Depletion of CD8+ T cells was performed 
by two injections of 75 µg CD8 mAb (clone 2.43; BioXCell) at days 10 
and 11 after transplantation.
IFN- determination in mouse serum. IFN- protein levels were mea-
sured using a multiplexed particle-based flow cytometry cytokine assay 
(R&D Systems) according to the manufacturer’s instructions.
Analysis of proliferation in vivo using BrdU. BL/6 CML mice received 
BrdU (Sigma; 0.8mg/ml in drinking water and 1mg i.p./day) on 2 consecutive 
Lineage depletion and flow cytometry. BM lineage depletion was 
performed using biotinylated antibodies against red cell precursors (Ter119), 
B cells (CD19), T cells (CD3), and myeloid cells (Gr1), MACS -biotin 
beads, and LS columns (Miltenyi Biotec).
Determination of granulocyte counts/microliter was performed using 
a VetABC animal blood counter (Medical Solution GmbH) in combination 
with FACS. All samples were analyzed on a BD LSRII and sorting was per-
formed on a BD FACSAria (BD). Data were analyzed using FlowJo soft-
ware (Tree Star).
Cell cycle analysis. FACS-sorted, linBCR/ABL-GFP+c-kithi were 
pooled and incubated in 1% PFA/PBS overnight at 4°C. Samples were per-
meabilized with 0.2% Triton X-100 for 30 min at 4°C and labeled with 
5 µg/ml DAPI (Roche).
Generation of p14 and p14xIFN-/ effector CTLs and memory 
cells. 106 splenocytes from p14 TCR transgenic (p14) mice or p14xIFN-
/ mice (all CD45.1+) were adoptively transferred to BL/6 mice. 18 h 
later, BL/6 mice were infected with 104 plaque-forming units of LCMV-
WE, and spleens were harvested 6 d later. For experiments using p14 
CD8+ effector T cells exclusively, cells were MACS-purified by CD8 
beads. 5 × 106 p14 CD8+ effector T cells were injected i.v. into recipient 
mice. For experiments using p14 and p14xIFN-/ CD8+ effector T cells 
in vivo, cells were FACS-purified for CD8, CD45.1, V2, and V8.1. 
3–5 × 106–purified effector T cells were injected i.v. into recipient mice. 
For the isolation of memory p14 cells, spleens of BL/6 mice were harvested 
6 wk after infection.
Generation of mature DC from HLA-A2tg mice. BM was flushed 
from femurs and tibias of HLA-A2tg mice using RPMI 1640 medium 
(Sigma-Aldrich) containing 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM l-glutamine. Erythrocytes were removed using 
RBC lysis buffer (QIAGEN). 2–3 × 106 BM cells were cultured in RPMI 
10% FCS supplemented with 50 µM 2-mercaptothanol and 10% (vol/vol) 
supernatant from a GM-CSF hybridoma cell line in nontissue culture–treated 
Petri dishes at 37°C and 5% CO2. After 6 and 8 d, half of the medium was 
removed and fresh medium was added. After 10 d, cells were transferred to 
tissue culture Petri dishes and 104 U/ml recombinant mouse (rm)-TNF 
(Prospec) was added to cultures. 2 d later, mature DC were harvested from 
the supernatant and analyzed by flow cytometry for expression of CD11c, 
MHC class II, CD80, and CD86.
Generation of HLA-A2–specific CD8+ effector cells. To induce an 
optimal CTL response in HLA-A2tg mice, the coexpression of both CTL 
and CD4 helper peptides on DCs was necessary (Bennett et al., 1997). 
Therefore, mature DCs from HLA-A2tg mice were pulsed with the CTL 
peptide b3a2 (105 M) in combination with the CD4 helper peptide p13 
(106 M) in RPMI 2% FCS for 90 min at 37°C and 5% CO2. DCs were 
washed twice and naive HLA-A2tg mice were vaccinated i.v. with 106 DCs 
at days 0, 2, 10, and 12 (Ludewig et al., 2000). At day 14, spleens from HLA-
A2tg mice were harvested and CD8+ T cells were purified by MACS, and 
then cultured in IMDM 10% FCS in the presence of 50 U/ml rm-IL-2 
(Prospec) and 0.01% 2-mercaptoethanol. Mature DCs from HLA-A2tg mice 
were pulsed as with the CTL peptide b3a2 (105 M) only and added to 
CD8+ T cell cultures at a ratio of 1:5 to 1:10 at the beginning of culture. 
Fresh DCs were added weekly. Cultures were maintained at 37°C and 5% 
CO2 for 3 wk. 2–3 × 106 MACS-purified CD8+ T cells were injected into 
HLA-A2tg CML mice.
Proliferation assay. 3 × 103 FACS-sorted LSCs were irradiated (10 Gy) 
and co-cultured with 1.5 × 104 naive or memory p14 CD8+ T cells in 96-
well V-bottom plates (Corning) for 4 d. For the last 18 h of culture, 0.5 µCi 
of 3H-thymidine (PerkinElmer) was added to each well. Next, cells were 
collected with a Packard Filtermate 196-Harvester (Packard Bioscience) on 
UniFilter-96, GF/C plates (PerkinElmer). Microscint-0 (PerkinElmer) was 
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